Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION 1 zenagamtide versus placebo in treatment-naive adults with type 2 diabetes
jRCT2031260641Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2026
- Modality
- Small Molecules, Peptides
01
Overview
Randomised trial of amycretin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Novo Nordisk. Primary endpoint: Change in glycated haemoglobin. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
amycretin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031260641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260641.